Protalix BioTherapeutics, Inc.

NYSE American PLX

Protalix BioTherapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.10

Protalix BioTherapeutics, Inc. Free Cash Flow Per Share is USD 0.10 for the Trailing 12 Months (TTM) ending September 30, 2024, a 170.39% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

Protalix BioTherapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -0.14, a 76.95% change year over year.
Protalix BioTherapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -0.60, a -76.09% change year over year.
Protalix BioTherapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -0.34, a 62.15% change year over year.
Protalix BioTherapeutics, Inc. Free Cash Flow Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -0.91, a 34.35% change year over year.

Key data

Date	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)

NYSE American: PLX

Protalix BioTherapeutics, Inc.

CEO	Mr. Dror Bashan
IPO Date	May 15, 1998
Location	United States
Headquarters	2 University Plaza
Employees	208
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Key trends

Past 5 years